Published eLetters
Guidelines
As a forum for professional feedback, submissions of letters are open to all. You do not need to be a subscriber. To avoid redundancy, we urge you to read other people's letters before submitting your own. Name, current appointment, place of work, and email address are required to send a letter, and will be published with your review. We also require that you declare any competing financial interests. Unprofessional submissions will not be considered or responded to.
- Page navigation anchor for RE: Clinical uncertainty in the development of therapeutics for addictionRE: Clinical uncertainty in the development of therapeutics for addiction
Current therapeutics for addiction include several broad classes of medications including atypical antipsychotics such as Quetiapine and Risperidone. Incidentally, D2 antagonism is the most commonly suggested pathway these medications have been purported to act through.
If there is a way to measure or quantify the interplay between Pavlovian incentive and hedonic processes, would we be able to develop medications that preferentially target different subregions of the ventral striatum? Or do these findings suggest another mechanism which should be utilized for therapeutic development?
Ultimately, it is difficult to determine the value of these results as we still lack a full understanding of existing mechanisms used for current treatment.
Competing Interests: None declared.
In this issue
